Melatonin: a hormone of the pineal gland
Melatonin is an endogenous hormone that is formed mainly in the pineal gland, a small structure in the centre of the brain. Its chemical name is N-acetyl-5-methoxytryptamine, its molecular formula is C13H16N2O2. It is an indoleamine and is derived biochemically from the amino acid tryptophan, which is first converted into serotonin and from there, in two enzymatic steps, into melatonin.
The substance was first isolated in 1958 by the dermatologist Aaron B. Lerner and colleagues from bovine pineal glands. The name refers to the observation that the extract made pigment cells of amphibian skin appear paler. Melatonin is not restricted to vertebrates: it has been detected in bacteria, unicellular organisms, fungi and plants, and small amounts occur in foods such as nuts, cherries, tomatoes and some cereals.
Light, darkness and the circadian system
Melatonin release follows a daily rhythm. Specialised light-sensitive ganglion cells in the retina, which contain the photopigment melanopsin, signal the ambient light level to the suprachiasmatic nucleus of the hypothalamus. This nucleus acts as the central pacemaker of the circadian system and controls the pineal gland. In darkness, synthesis rises; in light, especially short-wavelength blue light, it falls. Blood levels are therefore typically highest in the middle of the biological night and low during the day.
Because of this pattern, melatonin is used in chronobiology as a marker of internal time. The onset of melatonin release under dim light conditions, known in the literature as the dim light melatonin onset, is a standard measurement in research on shift work, jet lag and circadian rhythm disorders. Endogenous melatonin production varies between individuals and declines on average with increasing age.
Production and dosage forms
Melatonin in commercial preparations is produced by chemical synthesis; extraction from animal tissue is no longer used. Products on the market include immediate-release tablets, prolonged-release tablets, capsules, oral sprays, drops and gummies. Prolonged-release formulations are designed to release the substance over several hours rather than in a single peak. After oral intake, melatonin undergoes extensive first-pass metabolism in the liver, mainly by the enzyme CYP1A2, and its elimination half-life is short, in the range of roughly 30 to 60 minutes for immediate-release forms.
Legal status in Germany and the EU
The classification of melatonin differs by dose and by presentation. In Germany, melatonin-containing products are assessed case by case: preparations with higher doses, and those presented for medical purposes, are classified as medicinal products and are then either pharmacy-only or subject to prescription. A prolonged-release medicinal product containing 2 mg of melatonin has been authorised in the EU since 2007 for a defined group of adult patients and is available on prescription. Low-dose products are marketed in some member states as food supplements, and the boundary between food and medicinal product has been the subject of repeated court decisions.
Under Regulation (EC) No 1924/2006, two health claims concerning melatonin have been authorised in the EU; they are tied to defined quantities of 0.5 mg and 1 mg per portion and may only be used under the conditions laid down in the regulation. The German Federal Institute for Risk Assessment published an opinion on melatonin-containing food supplements in 2024 and pointed out gaps in the data, in particular on long-term intake.
What research has examined
Melatonin is one of the most frequently studied substances in sleep and chronobiology research. Findings are reported here as research results, not as expected outcomes:
- Jet lag. Trials in air travellers crossing several time zones have examined melatonin taken at the destination. A Cochrane review summarising ten randomised trials reported differences in self-rated jet lag scores compared with placebo; the trials were heterogeneous in design and in the time of intake.
- Shift work. Studies in night-shift workers have measured daytime sleep duration using sleep diaries and actigraphy. Reported differences were small, and the trials were short.
- Sleep onset latency. Meta-analyses of placebo-controlled trials in adults have reported shorter mean sleep onset latency in the melatonin groups, in the range of a few minutes. The authors noted high variability between trials and wide confidence intervals.
- Children and adolescents. Trials exist in children with neurodevelopmental conditions, but the number of participants is usually small and the observation periods are short. Data on the effect of long-term intake on pubertal development are lacking.
- Laboratory work. In cell culture, melatonin acts as a radical scavenger and binds to the receptors MT1 and MT2. Whether the concentrations used in such assays are reached in human tissue after oral intake is an open question.
Doses used in the published literature cover a wide range, from 0.5 mg to 10 mg, with many trials in the lower part of that range. Higher doses in these studies did not systematically correspond to larger measured differences. These figures describe study protocols and are not an intake recommendation.
Undesirable effects and interactions
The adverse effects reported most frequently in trials and in pharmacovigilance data are headache, dizziness, nausea and daytime sleepiness. Transient depressive mood, vivid dreams and disorientation on waking have also been described. More serious effects have been reported in rare cases, particularly with prolonged intake or in combination with certain medicines.
Melatonin is metabolised by CYP1A2, so substances that inhibit or induce this enzyme can alter blood levels; fluvoxamine and caffeine are examples discussed in the literature, as is cigarette smoke as an inducer. Interactions with anticoagulants, antihypertensives, antiepileptic medicines and sedatives have been described.
Groups for whom particular caution is noted
- People with autoimmune conditions
- People with epilepsy
- Pregnant and breastfeeding women
- People with depressive disorders
- Children and adolescents, because the influence on hormonal development has not been clarified
Driving and operating machinery after intake are mentioned in product information because of possible daytime sleepiness.
Open questions
- Long-term data. Controlled trials lasting longer than a few months are scarce, so the consequences of continuous intake over years are not known.
- Endogenous production. Whether regular external intake influences endogenous synthesis is disputed in the literature.
- Dependence. Physical dependence has not been demonstrated; psychological habituation has been discussed but not systematically investigated.
- Product quality. Analyses of commercial products in several countries have found declared and measured contents to differ considerably in a number of samples.
Summary
Melatonin is a well characterised hormone with a clear biochemical origin and a well documented daily rhythm. Research on external intake is extensive but heterogeneous, with short observation periods and small measured differences in many trials. Its regulatory classification in Germany depends on dose and presentation, and questions about long-term intake remain open. Anyone taking medicines or living with a chronic condition should discuss intake with a physician.